FidoCure® is the leader in Precision Medicine for Canine Oncology.
Public company, workplace, funding, and market signals
FidoCure is One Health Company’s canine cancer-care and precision-oncology platform, combining genomic testing, tumor profiling, AI/real-world-evidence analytics, and veterinarian-guided targeted therapy recommendations to improve treatment decisions for dogs with cancer.
Primary product
FidoCure canine precision-oncology platform (genomic testing + AI-driven therapy recommendations)
Founded
2018
Headquarters
Palo Alto, California, United States
Team size
10-20
Industry
Biotechnology
Sub-industry
Veterinary oncology / precision medicine
Offices
Business model
Stage
Series B / revenue-generating
Total raised
$32.1M
Latest round
Series B · Jan 2024
Latest amount
$15M
Leadership
Co-Founder & CEO
Benjamin Lewis
Co-Founder
Chief Medical Officer
Chief Product & Technology Officer
Head of Medical Affairs
Head of Communications
Director of Clinical Operations
Thaddeus Allen
Head of Science
Mission-driven, science-first, patient-centric, and capital-efficient; emphasizes cross-functional collaboration across veterinary, AI, and human-oncology stakeholders.
Pricing
Not publicly disclosed; case-based veterinarian-mediated service with pharmacy-partner fulfillment.
Differentiators
Technology
Customers
Competitors
Estimated revenue
Around $3M-$5M ARR (publicly reported at $3.6M in 2024)
Business Wire · May 2025
Researchers at FidoCure and Stanford published a Nature Scientific Reports paper showing genomic biomarkers and targeted therapies improved outcomes for canine hemangiosarcoma, including reported survival benefits for treated dogs.
FidoCure blog · Jan 2025
FidoCure introduced Fetch™, its proprietary AI engine for analyzing real-world canine cancer data to identify promising therapies and extend its precision-oncology platform.
Business Wire · Oct 2024
FidoCure announced new canine hemangiosarcoma findings ahead of the 2024 Veterinary Cancer Society conference, highlighting research on the most prevalent and deadly canine cancer.
Forbes · Aug 2024
Forbes featured CEO Christina Lopes discussing the company’s growth, patent milestone, and translational one-health strategy linking canine and human oncology.
Business Wire · Aug 2024
The USPTO granted FidoCure an industry-first patent for an AI-driven, mutation-guided canine cancer treatment approach, with the company stating it would seek FDA approval for products.
0 jobs at FidoCure®
Check back later for new openings